Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
New
Job vacancy:
Quality Assurance Officer
Advent Bioservices Ltd - Cambridge CB22 3JH
Temporary - Temporarily remote
https://www.indeed.co.uk/Advent-jobs?vjk=0e5b55a5dde7387a
New
JOB VACANCY: Quality Assurance Officer
Location: Sawston, Cambridgeshire
Position Type: Temporary (6 months)
Hours: Full Time (37 hr/wk)
We are looking for an experienced and proactive Quality Assurance Officer to support the Quality Assurance team in validation, operation and management of the Quality Management System.
Responsibilities will include:
• Writing Quality documents, Standard Operating Procedures (SOPs) and policies
• Supporting the management of the controlled document system including SOPs, labelling, validation plans, change control, non-conformance, risk assessments and reviewing CAPAs
• Participate in the inspection process by the MHRA and HTA for manufacturing and storage licensing
As a team player, you will have excellent written and verbal communications skills with a meticulous and proactive approach to work.
You will have the following experience/qualifications:
• Experience in writing QA documents, especially Standard
Operating Procedures, labels and forms
• Experience within a GMP facility and working in a sterile
manufacturing facility
• A sound scientific understanding of cell therapies
• BSc or MSc in a life sciences subject, or comparable experience
We offer excellent opportunities for career progression along with training and the chance to be a part of a growing organisation. We also offer an attractive base salary and benefits package.
The candidate must have the right to work in the UK.
Interested candidates are encouraged to submit a CV and a supporting letter to recruitment@adventbio.uk.
Closing date for applications is 4 September 2020
https://www.adventbio.uk/job
NWBO owns the 20 year lease on the Sawston building, along with the option to renew for another 20 years, and all the build out at Sawston. Advent owns the personnel that's overseeing the build out. There's really nothing for Advent to sell, other than their current contracts with Northwest. And why would they do that?
ex, not a big deal, but some of that equipment is listed under “Construction in Progress” which is about $1.5M. Contrary to what you say, it appears that Northwest Bio will own the equipment, not Advent.
Construction in Progress
In connection with the Company’s manufacturing facility in U.K, the Company has incurred and is incurring costs with certain vendors to design and build out the initial stage of the facility. Additionally, the Company purchased certain manufacturing equipment that will be installed in connection with the buildout. These costs were all capitalized and recorded as part of construction in progress as of June 30, 2020. Upon completion of the buildout, all costs associated with the buildout will be recorded as manufacturing equipment or leasehold improvement and amortized over the estimated useful life of the facility.
Dog logic,
Correct!
I have received a handful of replies from the UK authorities, the last one a few days ago.
The emails and any files transmitted with them are confidential.
I am not going to post them.
NOTE: I am very excited about the recent developments in Europe.
survivor1X,
At the time of the "hold on recruitment" (Aug.2015), all patients who had lived at least 37 months after surgery were all still alive. One flat line on the OS curve beyond month 37. That is unique in a trial for GBM patients. Something to think about when a "hold on recruitment" is imposed.
I suspect that the shortest life in the Top 100 could very well be in excess of 4 years and the median could now be approaching 72 months.
ilovetech, ours is way higher than 17.7months. I think 23.1months blended. No Threat at all.
Phase 2a study to evaluate the safety, pharmacokinetics, and clinical activity of the PI3K / mTOR inhibitor paxalisib (GDC-0084) given to glioblastoma (GBM) patients with unmethylated MGMT promotor status.
https://kza.irmau.com/irm/PDF/42fa1764-4329-42d8-9fbc-c9e2433b3ecc/PaxalisibposterpresentedatAACRvirtualmeeting
flipper44,
I think you are referring to this publication:
"TCR Sequencing Can Identify and Track Glioma-Infiltrating T Cells after DC Vaccination".
https://cancerimmunolres.aacrjournals.org/content/4/5/412
Co-author Dr. Jian L. Campian, of Washington University and Siteman Cancer Center and member of the Steering Committee:
“The overall patient population in the trial appears to live longer than we would typically see with current standard of care, and 30% of the patients have lived much longer than we would expect, given the typical course of this cancer,” Dr. Campian said.
“In general, patients with this cancer live 15 to 17 months. The surprising part was that the 100 ‘extended survivors’ don’t appear to have the usual characteristics associated with a good prognosis. We are continuing to study these patients to understand why they have done so well.”
IMO, it is telling that Dr. Steven Brem is on the Steering Committee.
longfellow95 Friday, 07/06/18 12:02:31 PM
Re: None
Post #
181412
Well, it's gratifying to know that in addition to the extremely well qualified Scientific Advisory Board, there is also an extremely well qualified Steering Committee for the trial, and they are all amongst the list of co-authors.
I had not heard them named previously until LP named them at the ASCO meeting.
Steering Committee:-
Dr. Steven Bremm.
Chief, Neurosurgical Oncology, Co-Director, Penn Brain Tumor Center, Professor of Neurosurgery, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania
Dr. Fabio Iwamoto.
Dr. Iwamoto is a neuro-oncologist whose previous training includes a neurology residency at NewYork-Presbyterian/Weill Cornell Medical Center and a neuro-oncology fellowship at Memorial Sloan-Kettering Cancer Center. For over three years, Dr. Iwamoto was an attending physician and an investigator at the Neuro-oncology Branch, a trans-institute branch of the National Cancer Institute and National Institute of Neurological Disorders and Stroke, in Bethesda, MD. At the intramural NIH, Dr. Iwamoto was a principal investigator in early phase clinical trials for brain tumors and worked with laboratory and computational scientists on several translational projects in brain tumors.
Dr. Iwamoto was recruited to Columbia University as the Deputy Director of the Neuro-oncology Division and is actively developing the clinical and translational research components of this program. He is an expert in the diagnosis, management, and treatment of brain and spinal cord tumors as well as neurological complications of cancer.
Dr. Jian Campian.
https://oncology.wustl.edu/people/faculty/Campian/Campian_Bio.html
Dr. John Trusheim.
Actions speak louder than words may be trite, but is often true.
flipper44
Saturday, 05/16/15 09:31:28 AM
Re: None
Post 34849
Philadelphia, Pennsylvania, United States, 19104
Contact: Suzanne Frangos, RN, CNRN 215-285-2885 suzanne.frangos@uphs.upenn.edu
Contact: Dept. of Neurosurgery (215) 615-5436 Neurosurgery-NCRD@uphs.upenn.edu
Principal Investigator: Steven Brem, MD
Still, the info is even more relevant today than in 2019.
New interview with Dr. Steven Brem.
forumreader35 Thursday, 04/11/19 09:21:53 AM
Re: None 0
Post #
222208
of 300388
Select Novel Approaches to Glioblastoma—Part 2
Published in Oncology and Expert Opinion / Interview · April 10, 2019
Interview with
Steven Brem MD
Interview by
Aman Shah MD
https://www.practiceupdate.com/content/select-novel-approaches-to-glioblastoma-part-2/76518
Dr. Shah: So, we spoke earlier in part one of this program about some of the new research that you’re doing with DNA vaccines and conjugates with Pseudomonas toxin. Could you tell us some other interesting research you’re doing on novel therapies in neuro-oncology?
Dr. Brem: Yes. We just completed a study with Tocagen, which is a viral therapy, which will also stimulate the immune response and also uses a novel form of chemotherapy where it takes an antifungal drug that is converted genetically to an oncolytic drug. So it’s a very clever approach, and that’s a large multi-center study and that’s being analyzed right now. And we learned at this meeting that their plans to roll out a new trial through the NRG for newly diagnosed using viral therapy and we’ve heard of the poliovirus, we’ve heard of the many viral studies coming from multiple centers in Boston, Houston, and so on, and about viral therapy. And whatever the virus is, they all are oncolytic. They kill the new glioma cell, liberate new antigens, or neoantigens, which are then recognized by antigen presenting cells.
We’ve also been very active in the DCVax, which was started at UCLA but now extended to Penn and other sites. And the interesting thing of that trial, which we reported some preliminary data, is that a large percentage of the patients are now living beyond 3 years, so that is a unique approach in that the patients own tumor creates their very individual vaccine looking at their own panel of antigens. So we’re excited by that approach and we’ll be hearing more about that in the future.
Dr. Shah: Okay, so my understanding of the DCVax is that you have to take the tissue out and then generate something against the dendritic cells within that admixture.
Dr. Brem: Yes.
Dr. Shah: Could you tell us a little bit more about where that therapy stands as of now and what kind of efficacy we're getting?
Dr. Brem: Well, a very large multi-national study was concluded and so that is going to…as the data matures, that will be going to FDA. We hope that that gets approved. We don’t know, but it’s an exciting study.
Dr. Shah: Okay, so talking about getting tumor cells out and generating something against it. It seems that you are also either working on or are involved with CAR T cells in glioblastomas, so please walk us through how that works.
Dr. Brem: Well, that is an exciting effort. It’s being led at the Abramson Cancer Center by Donald O’Rourke and his team, Zed Binder. I’m involved in that group, and it has just been funded by the Abramson Cancer Center as a translational center of excellence, so there’s a huge effort underway with neurosurgery and the Parker Institute, Abramson Cancer Center, Carl June’s Laboratory, many other laboratories trying to develop the next generation of CAR T cell. So we are…we just published a first-in-man phase I human trial that showed biological activity. And now because we’re dealing with a tough foe, the glioblastoma, we’re working on potentiating this by taking down some of the tumor defenses, looking at checkpoint inhibitors, combining it, supercharging the CAR T cell vaccine in a combination therapy, so that will be the next generation. That’s the future.
Dr. Shah: So, my understanding is that perhaps part of the reason why PD-1s have not been as promising in glioblastomas is glioblastomas somehow seem to not be very rich in T cells when you sample them, so there’s something stopping them.
Dr. Brem: There’s stromal barrier and there are inhibitors like TGF-ß, IL-6, the TNF-a, there’s cytokines. Also, we’ve been very interested in looking at macrophage polarization. And I’m part of a group that published this year in Nature Communications led by Yi Fan, who presented at this meeting, showing that if you block IL-6, you could redirect the macrophage from a tumor-suppressing state, the M2 state, to the M1 immunostimulatory state, so we hope to partner with pharma on that and develop the clinical trials based on that discovery.
Dr. Shah: That is fascinating, and of course, the CAR T cell strategy makes perfect sense because you create them in vitro and then put them in.
Dr. Brem: Yeah, so ultimately, we feel by attacking the tumor microenvironment as well as creating a vaccine directed to the antigens on the tumor, we’re going to have really a new class of therapy.
Nice to see the words “ahead of schedule”. Though this is all just five minutes of me scanning some public documents so don’t read too much into it and it may not even be in relation to NWBO at all.
flipper44,
A CHANGING WORKPLACE
Russ and Sully talk with Les Goldman about the latest at Northwest Biotherapeutics. Then, their first live guests joins them in the new studio- Bob Babbitt and Dan Negroni.
Original Air Date: July 24, 2020
https://www.bizvod.com/tv/search/video/3fdc1b94c2f914241ec3c063d752793d
VIRTUAL EVENTS
Russ and Sully talk with Les Goldman about immunotherapy for cancer, and Troy Hazard about the virtual events space. Then, Andrea Woroch discusses the do's and don'ts of personal finances during COVID. Plus, Liz Bryant shares tips on the homebuying market.
Original Air Date: August 6, 2020
https://www.bizvod.com/tv/search/video/21a82f63f53165b9a9352944f08affcb
les goldman spoke on 7/24 and 8/6 on Big Biz.Was there any difference in the approval process guidance he gave on these two occasions ?
Glad that Lykiri pointed out that this is not just LG, but NWBO as a company spinning this crap
v. Efficacy of DCVax Products
Finally, Plaintiffs object to Defendants' statements made at the January 13,
[273 F.Supp.3d 592]
2014 BioTech Showcase and, to a lesser extent, the January 12, 2015 BioTech Showcase regarding the efficacy of DCVax products in general. ECF No. 22 ¶¶ 50, 78. Plaintiffs claim that "neither DCVax-L nor DCVax-Direct had demonstrated an 80+% response rate in any well-designed clinical trial," and "neither DCVax-L nor DCVax-Direct had demonstrated a 1-½ year extension in median overall survival or progression free survival over standard of care in any well-designed clinical trial." ECF No. 22 ¶ 50. Plaintiffs further state that "NW Bio had no evidence from well-controlled trials showing any `extensions of the time to disease progression, progression free survival, and extensions of overall survival in the realm of years.'" Id. ¶ 79.
These claims are either flawed or suffer from a lack of clarity. If, for example, Plaintiffs are alleging that NW Bio falsely reported a greater-than-80% response rate for DCVax, Plaintiffs may have stated a claim. However, in their Opposition, Plaintiffs merely explain that "these representations were misleading not because of what they affirmatively stated, but because of the adverse interim Phase III results they omitted." ECF No. 28 at 40. Plaintiffs fail to show how this is an actionable omission, as they do not adequately plead facts demonstrating that an interim efficacy analysis took place or what such analysis revealed. Indeed, the only reasonable inference with respect to these allegations, as stated, is that Plaintiffs disagreed with Defendants' methodology, interpretation of the data, or expressions of optimism. In that regard, they fail to allege how these statements are false or misleading. See Padnes v. Scios Nova Inc., No. C 95-1693 MHP, 1996 WL 539711, at *5 (N.D. Cal. Sept. 18, 1996) (holding that "[t]he fact that plaintiffs disagree with the ... researchers and with defendants about the import of the ... data does not make defendants' summaries of the study false or misleading."); In re Pfizer, Inc. Sec. Litig., 538 F.Supp.2d 621, 631 (S.D.N.Y. 2008) (noting that "`corporate officials need not present an overly gloomy or cautious picture' so long as `public statements are consistent with reasonably available data.'"); ATSI Commc'ns. Inc. v. Shaar Fund. Ltd., 493 F.3d 87, 99 (2d Cir. 2007) (stating that allegations in securities fraud claims "that are conclusory or unsupported by factual assertions are insufficient.").
Plaintiffs additionally object to the following statement from Defendant CEO Powers: "In terms of efficacy, again, we are still in clinical trials, we have to see how the further trials read out there [are] no guarantees, but [what] we've seen up `til now has been quite encouraging.'" ECF No. 22 ¶ 78. This is quite unlike the defendant's statement in In re Medimmune. Inc., cited by Defendants, ECF No. 26-1 at 27. in which the company Vice President stated: "There's absolutely no question about efficacy," in regards to defendant's drug Respivir. There, the Court held:
It is one thing to declare enthusiasm about the results from this study and the implications for preventing this serious illness, ... [or] that a high dose of Respivir significantly reduced the severity of RSV and significantly reduced the frequency of RSV related hospitalizations. It is quite another thing to make a statement that falls into the second category of arguably false or misleading statements, i.e. that Respivir was unquestionably efficacious.
In re Medimmune. Inc. Sec. Litig., 873 F.Supp. 953, 967 (D. Md. 1995). Here, Defendants did not represent that DCVax was "unquestionably efficacious," nor do Plaintiffs allege that the reported results in the presentation were false.
Therefore, the Court cannot find that Plaintiffs have stated a claim with respect to the efficacy of DCVax Products.
Les has been saying '85% immune response' for years. This is not new.
The long term data from these clinical trials shows that more than 80% of the patients who received DCVax(R)-Brain showed a clinical response. In contrast, the typical response rates for cancer drugs are in the range of 20 to 25% of patients, and have been as low as 13% of patients with some approved cancer drugs.
("NWBT" or the "Company") today announced the most recent long-term follow-up data, through June 15, 2008, from its prior Phase I and Phase I/II clinical trials with DCVax(R)-Brain, which began in 2000 and 2003, for patients with Glioblastoma multiforme, the most lethal type of brain cancer. This long-term data shows that 84% of patients who received DCVax(R)-Brain in these trials have so far lived longer than the median survival of 14.6 months under standard of care, 68% of the patients have so far lived more than 2 years, 58% of the patients have so far lived more than 2-1/2 years, 42% have so far lived more than 3 years, and 26% have so far lived more than 4 years, with patient surviving as long as 8 years to date. The median survival in thenpatients from these trials is now 36.4 months, under a standard Kaplan Meier analysis.
DCVax(R)-Brain is a groundbreaking personalized vaccine that takes a
patient's own immune cells and trains them in the laboratory to attack the biomarkers from that patient's own tumor cells. The 10-day manufacturing process produces several years of personalized vaccine for a patient, making DCVax(R)-Brain an "off-the-shelf" product for that patient throughout the treatment period. DCVax(R)-Brain is administered as a simple injection under the skin, similar to a flu shot, and is not toxic as chemotherapies are.
The most recent data provides an update for the period since December 31, 2007, concerning both disease progression and overall survival. During that period, only one of the nineteen patients experienced disease progression (at 59.5 months), and only one patient died (at 37.8 months).
The long term data from these clinical trials shows that more than 80% of the patients who received DCVax(R)-Brain showed a clinical response. In contrast, the typical response rates for cancer drugs are in the range of 20 to 25% of patients, and have been as low as 13% of patients with some approved cancer drugs.
DCVax(R)-Brain is now in a large, Phase II clinical trial designed and
powered as a pivotal trial, which is currently enrolling patients at 11
medical centers across the U.S. (listed at http://www.nwbio.com).
sentiment,
after ASM, IMO.
Quote:
85% patients responded when treated with DCVax-L which he said was impressive compared to toxic chemotherapy and radiation which responded with measly 25%. He believed that should not be overlooked at all.(sukus post 299015)
That is a total jibberish statement.(exwannabe)
LG is such a pathetic pumper it is a joke. He manages to make the company look worse every time he says garbage like this.(exwannabe)
We also have to work with the regulatory bodies, and we probably ought to do that now, right, not even waiting, because we want this to be available to all the patients. Again, while it’s very nice about these studies… yes, those patients who are in better prognostic groups are going to benefit more… but there is a benefit to all patients. We want this available to absolutely everybody.
longfellow95,
I can't find a YouTube link.
Min. 8.52s
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157474296
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157474721
Ex,
Maybe you can start your DD here:
Pictured from left to right:
Dr Helen Spoudeas, Founder of SUCCESS Charity and Consultant Paediatric Endocrinologist; Neuroendocrine Oncology Lead at Great Ormond Street Hospital,
Derek Thomas MP, Chair, All-Party Parliamentary Group on Brain Tumours
Sue Farrington Smith, Chief Executive, Brain Tumour Research
Erik Ramos, Special Projects, NorthWest Biotherapeutics
Dr Navid Malik, Non-executive board director, NorthWest Biotherapeutics
Richard Crowther, Trustee of SUCCESS charity, Brain Tumour Research Activist, and parent to a child diagnosed with brain tumour
Ex,
I am not talking about Marketing Authorisation by the European Medicines Agency (EMA)
And please tell me how LG knows this.
hope4patients,
Thank you!
But larger scale does not work well when each batch is per person.
Once it is automated end-to-end, that all goes out of the equation, because you just have rows and rows of these machines in a warehouse space. So you couple that with the batch manufacturing, and it's a step-change in terms of further enhancement of the economics. And so, everyone is busily working on automation. Umm, we think that's a couple-of-year process from where we are today. And we're working from some of the biggest and the best from all over the world.
Harvesting Dendritic Cells with microden needs about 7 days. That means one machine can harvest DCs from 4 patients per month. If Advents Bio sets a target to treat 50 patients per month, Advent would need about 13 machines.
Dear XXXXXXXXX
………
Unfortunately MicroDEN equipment was discontinued and it is no longer available.
………
In case Dendritic cell production is of interest, I would suggest to consider T-flask, or Hyperflask technology (for bigger scale) from Corning.
It's not the only anomaly. On the Top 100, it is stated on Slide 24, that 75% had a complete resection. On the next slide, it is 71%...
Not of any huge significance, but it's the sort of anomaly that they really need to avoid in the official trial outcome stats.
The AF's of the world will pore all over the final readouts, looking for any anomalies; so as to cast any doubt that they can on the data.
Unknown factors: sub-group with extended survival
Approximately 30% of the ITT population (n?=?100) showed particularly extended survival, with a KM derived mOS estimate of 40.5 months. This is not fully explained by known prognostic factors, as only some of these patients had positive prognostic factors: only 29% were younger than 50 years of age, 65.9% had methylated MGMT, 71% had a complete resection, and only 8% of these patients had all three positive prognostic factors. These patients will be the subject of extensive further analyses and research.
https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-018-1507-6#Abs1
Any idea of the findings of the investigation?
He may just be a doctor / scientist who believes in his therapy, but hasn't got a few hundred million dollars (and 10yrs) spare, to go through a full trial process, and that's why he resents the whole BP status quo, so personally I won't jump to judge him.
We know that Laura from the UK is being treated at one of these clinics, probably this one.
July 30, 2019
More excitingly, Laura and I are currently in Cologne where we have just started immunotherapy treatment at the IOZK clinic under Professor Van Gool.
This treatment starts with electrohyperthermia treatment and the Introduction of an oncolytic virus to help her immune system to recognise and identify the tumour cells.
We will be returning to Cologne for 5 days every month whilst Laura is still on chemo and when that ends she will return for further sessions where she will receive the dendritic cell vaccine, manufactured from her reprogrammed white blood cells.
Obviously we have no guarantees but we’re optimistic that this is the best course of action for her.
https://www.gofundme.com/f/ngdq37-doing-it-for-laura
11. Price per drug. The price for IMI treatment at IOZK is about 55,000 Euro and is based on the legally fixed prices for ambulant treatment in Germany. This has to be payed privately or it is covered by health insurances. The price just covers the enormous investments for GMP production by this private non-profit enterprise.
https://www.mdpi.com/2227-9059/8/8/237/htm
longfellow95,
Thank you for the information about DC therapy IO-VAC®.
Three years ago, Stefaan van Gool, MD, a high-profile pediatric oncologist in Belgium, who has been developing a cancer vaccine for brain tumors, was being investigated for possible misconduct and ethical violations.
I do think that the actual end date for the trial dates back to some time before the ASM, possibly to a time slightly before the PR announcing the ASM date... in February.
I think it is Dr Nesselhut at IOZK who has a fairly OK reputation.
And of course NWBO knew of thus connection.
the DMC Chair himself serves on the Scientific Advisory Board for the same company (and forgets to tell anyone)...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146672036
FORM 10-K
ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2015
Competition
The biotechnology and biopharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. A large and growing number of companies are actively involved in the research and development of immune therapies or cell-based therapies for cancer (including Juno, Kite, Bellicum, Atara, Argos, Agenus, Asterias and many others).
https://www.sec.gov/Archives/edgar/data/1072379/000114420416088301/v433750_10k.htm
FORM 10-K
ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2016
Competition
The biotechnology and biopharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. A large and growing number of companies are actively involved in the research and development of immune therapies or cell-based therapies for cancer (including Juno, Kite, Bellicum, Argos, Agenus, Asterias and many others).
https://www.sec.gov/Archives/edgar/data/1072379/000114420417020754/v464066_10k.htm
FORM 10-K
ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2017
Competition
The biotechnology and biopharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. A large and growing number of companies are actively involved in the research and development of immune therapies or cell-based therapies for cancer (including Juno, Kite, Bellicum, Argos, Agenus, Asterias, Dandrit, Immunicum, Sotio, Tocagen and many others)
The company is question was not a competing company.
Competition in the biotechnology and biopharmaceutical industry is intense, rapidly expanding and most of our competitors have substantially greater resources than we do.
The biotechnology and biopharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. A growing number of other companies, such as Juno, Kite Bellicum, Argos, Agenus, Asterias, Dandrit, Immunicum, Sotio, Tocagen and many others, are actively involved in the research and development of immune therapies or cell-based therapies for cancer.
https://www.sec.gov/Archives/edgar/data/1072379/000114420418020971/tv491101_10k.htm
Brad Silver:
Patient Advocate at Northwest Biotherapeutics.
https://www.linkedin.com/in/brad-silver-170304176/
Then in Dec 2014 LP said there would be an efficacy IA in H1 2015.
Anticipated Milestones and Catalysts in 2015.
DCVax-L Phase III Trial Program
*
* First interim analysis for efficacy – independent DMC review
I will check, Hope. It might have been someone else, but the sameness quote is something we discussed on this board. I. Hoping Senti or someone who does a better job than I do at filing these quotes, will jump in with the source.
“The principle and the platform are the same”
sentiment,
Steve White first diagnosis (July 2016) was GBM. Surgery Aug.5, 2016. (95 % of the tumour removed)
Here is his story:
JOURNEY WITH BRAIN CANCER - STEVE WHITE BEATING CANCER WITH DENVAX
Steve White, from Eccleston, was diagnosed with an aggressive life-threatening tumour called glioblastoma multiforme wild-type in July last year.
Can you or anyone explain to me what this Daniel Moore will do exactly ?
This guy is not a software developer but a network engineer.
typically someone who will install working places, prepare the network connection between staff, prepare cloud storage, purchase and install needed software etc. Since NWBO only employs 12 people it looks to me they are preparing to hire a lot more staff all in need of a network, working place, cloud storage, etc, especially when working remotely.
You dont hire a network CTO if you are not an internet company and only have 12 people working, unless you have or planning to hire many employees
anders2211,
Steve White is a British patient who had treatment with APCEDEN in India.
He was diagnosed with glioblastoma multiforme wild-type in July 2016.
https://www.sthelensstar.co.uk/news/16907299.steve-white-thanks-supporters-after-news-that-brain-tumour-has-returned-despite-recent-surgery/
He has done a lot of volunteer work for the Brain Tumor Charity in the UK.
https://www.thebraintumourcharity.org/media-centre/news/policy-news/launch-less-survivable-cancers-taskforce-petition/
https://www.change.org/p/nhs-england-double-the-survival-rate-of-the-least-survivable-cancers-by-2029
Unfortunately, in the early hours of Thursday, October 3, 2018, Steve dies in Willowbrook Hospice.
https://www.sthelensstar.co.uk/news/17983494.funeral-inspirational-brain-tumour-fighter-steve-white-take-place-today/